Slide 1: Responding To Australia's Mental Health Crisis
ASX : EMD For personal use only Responding To Australia’s Mental Health Crisis Advanced therapies. Compassionate care. 28 August 2025 Company Update
Slide 2: Disclaimer
Disclaimer This presentation has been prepared by Emyria Limited ACN 625 085 734 (Company or Emyria). This presentation is not a financial product or investment advice or recommendation, offer or invitation by any person or to any person to sell or purchase securities in Emyria in any jurisdiction.
Slide 3: Corporate Overview
Corporate Overview ASX: EMD Trading Information For personal use only Share Price Last Traded Share Price A$0.050 12-Month low / high A$0.021 / 0.058 Shares Outstanding3 664,160,825 Unlisted Options2 150,390,328 Market Capitalisation 1 ~A$32.0M Last Cash Position 2 ~A$4,685M Substantial Shareholder
Slide 4: Mental Health Is Australia's #1, Rising, Chronic Health Problem
Mental Health Is Australia’s #1, Rising, Chronic Health Problem Inaki Ereno For personal use only Figure2 : Types of serious illness by age and sex, 2009 to 2021 Bupa CEO 18% 16% Depression / Anxiety 14% 12% 10% 8% 6% Mental health is the new pandemic Cancer but the provision of mental health … 4% s
Slide 5: Major Funders Are Spending Hundreds of Millions Each Year on Mental Health
Major Funders Are Spending Hundreds of Millions Each Year on Mental Health For personal use only Private Department of Other Health Insurers Veterans’ Affairs Insurers The Government spends Life insurers … paid out more than $2B $300M/yr on veteran mental health each year. 2 $2.2B in 2024 spent by M
Slide 6: Australia's Unique Opportunity
Australia’s Unique Opportunity An Access Pathway For Psychedelics to Treat our Most Serious and Urgent Mental Health Conditions For personal use only MDMA-assisted therapy Australia for PTSD is the FIRST jurisdiction in the Psilocybin-assisted therapy world to reschedule two promising treatments for
Slide 7: Total Addressable Market | PTSD
Total Addressable Market | PTSD Adults with difficult to treat PTSD in Australia For personal use only Early Target Markets ~29,000 current patients With Hospital Cover (~5% Adults 2) Australian Adults Serviceable Addressable With PTSD Market (SAM) ~34,000 current patients Veterans (~17% of Veterans
Slide 8: Total Addressable Market | Treatment Resistant Depression
Total Addressable Market | Treatment Resistant Depression Adults with difficult to treat depression in Australia For personal use only Early Target Markets ~20,000 current patients with Hospital Cover (~5% Adults 2) Australian Adults With Serviceable Addressable Major Depression Market (SAM) ~18,300
Slide 9: Emyria Has Overcome Major Barriers To Psychedelic Delivery
Emyria Has Overcome Major Barriers To Psychedelic Delivery And Is Now Building An Operational Moat For personal use only Skilled Secure Therapists Drug Supply Third Authorised Party Prescribers Funding Proven Fit-for- Purpose Clinical Model Facilities 9 Advanced therapies. Compassionate care.
Slide 10: Emyria's P-AT Treatment Model
Emyria’s P-AT Treatment Model Medication, ~90 hours of Supervised Intensive Psychotherapy, Follow-Up For personal use only ACTIVE TREATMENT PROTOCOL DOSING DOSING DOSING CYCLE 1 CYCLE 2 CYCLE 3 FOLLOW-UP PERIOD SCREENING AND (12 months from last PREPARATION Dosing Treatment Cycle) Dosing Dosing Day
Slide 11: Emyria's PTSD Program Is Delivering Results
Emyria’s PTSD Program Is Delivering Results Case Study Kate | From “Permanent Disability” To Back at Work For personal use only MDMA-AT 5 years commenced PCL-5 < 30 70 Kate’s story: First responder 60 • PTSD due to cumulative workplace traumas 50 • Myriad of therapies: EMDR, in-vivo, ACT, CBT, mindf
Slide 12: Emyria's PTSD Program Is Delivering Durable Results
Emyria’s PTSD Program Is Delivering Durable Results Durable symptom and quality of life improvement, beyond 6 months from a single treatment Average PCL-5 1 Scores by Visit For personal use only (up to 6 months follow-up) Typical last treatment Emyria Real-World Data as of August 1st 2025 >60% of pa
Slide 13: Emyria's PTSD Program Is Delivering Results
Emyria’s PTSD Program Is Delivering Results Durable symptom and quality of life improvement, beyond 6 months from a single treatment Baseline For personal use only Our Empax Model matches Phase 3 trial outcomes out to 6 months. % of patients with PTSD diagnosis after course of treatment 1 0% drop-ou
Slide 14: Medibank Agreement
Medibank Agreement Emyria is the only provider Medibank has currently partnered with For personal use only Multi-year agreement1 Fully fund eligible, screened patients1 Uncapped patient numbers1 Initially MDMA-AT for PTSD1 Treatments have commenced in Perth2 Treatment to take place in hospital setti
Slide 15: Other Funders
Other Funders DVA > Workers Compensation > Others For personal use only Workers Compensation and other funders Case by case funding approval occuring First responders more likely to experience PTSD2 DVA to fund Psychedelic Assisted Therapies for its members1 1.https://www.blackdoginstitute.org.au/ne
Slide 16: Emyria's PTSD Program | Return-To-Work Progress
Emyria’s PTSD Program | Return-To-Work Progress To Date, 10 Out of 10 Patients With Work-related PTSD Have Returned To Work 6 M Post-treatment For personal use only 6-8 weeks 6-months 0% working 25% planning return to work 100% back to gainful Start of treatment employment End of treatment 6m post t
Slide 17: Emyria's Funded Care Pathways Pipeline
Emyria’s Funded Care Pathways Pipeline Medibank’s PTSD program in WA is the first of many potential funded care pathways Scoping For personal use only Planning Payer 1 Payer 1 (Melbourne) (Melbourne) Active 1 Payer 2 Payer 2 Payer 1 (Perth) (Perth) (Brisbane) Payer 2 Payer 1 Payer 1 (Brisbane) (Sydn
Slide 18: Accelerating a National Roll-out
To Meet Rising Patient Demand, Emyria Is Accelerating a National Roll-out For personal use only (1) Community Clinic 1 3 1 2 (2) Perth Clinic 2 Current Near term potential sites Sites SOURCES: 1. See ASX release 14th April 2025 (3) Avive Clinic (QLD) 3 2. See ASX release 29 July 2025 18 Advanced the
Slide 19: Emyria's Growth Strategy
Emyria’s Growth Strategy Secure Site Partners > Grow Capacity > Optimise Utilisation Currently active or in For personal use only Additional East Coast preparation sites under consideration Total Funded Dosing Days Available / week Future target Avive site active (Qld) Expansion within WA 1 35 WA 10
Slide 20: Upcoming Milestones
Emyria (ASX:EMD) | Upcoming Milestones Target activities For personal use only Expand funded programs to Grow capacity nationally include Depression Treatment via new site partners Expand funders for our Optimise utilisation to programs grow revenues 20 Advanced therapies. Compassionate care.
Slide 21: Why Invest Now?
Why Invest Now? Unique Timing. Proven Model. Overcome High Barriers To Entry. Programs Funded. For personal use only is tackling some of the most serious health challenges of our generation First Mover High Barriers Immediate Growth Advantages Overcome Potential 21 Advanced therapies. Compassionate
Slide 22: Emyria Board
Emyria Board Significant Clinical Services & Global Innovation Expertise For personal use only Greg Hutchinson Dr Michael Winlo Dr Karen Smith Dr Mohit Kaushal Prof Sir John Tooke Executive Chairman Executive Director Non-Executive Director Non-Executive Director Non-Executive Director Health Servic
Slide 23: Contact Information
Contact Information For personal use only Greg Hutchinson ghutchinson@emyria.com Mary-Ann Rennie mrennie@emyria.com Investor / Visit Our Media Inquiries Investor Hub investors@emyria.com